Pharmacological management of epilepsy: recent advances and future prospects.
There is still a need for new antiepileptic drugs (AEDs) as the clinical efficacy, tolerability, toxicity or pharmacokinetic properties of existing AEDs may not be satisfactory. One new AED has recently been approved (rufinamide in 2007) and six others are in late-stage development (phase III and onwards) [brivaracetam, carisbamate, eslicarbazepine, lacosamide, retigabine and stiripentol]. The purpose of this review is to provide updated data on proposed mechanisms of action, efficacy and tolerability on these new AEDs, and to discuss the rationale for their development and possible advantages compared with existing treatment, based on recent publications and MEDLINE searches.Rufinamide, brivaracetam and stiripentol have been given the status of orphan drugs. Rufinamide was approved in Europe in 2007 for the use in Lennox-Gastaut syndrome. Brivaracetam has gained orphan status for development in progressive and symptomatic myoclonic seizures in Europe and the US, respectively. Stiripentol has gained orphan status in children with Dravet's syndrome and pharmaco-resistant epilepsy. All of these drugs demonstrate efficacy as adjunctive therapy in partial seizures. Three of the drugs are derivatives of existing AEDs: brivaracetam is a derivative of levetiracetam with improved affinity for the target molecule; carisbamate is a derivative of felbamate with improved tolerability; and eslicarbazepine is a derivative of carbamazepine with less interaction potential and no auto-induction. Lacosamide, retigabine, rufinamide and stiripentol are new compounds, unrelated to other AEDs.Further investigation and development of new broad-spectrum drugs is important for improved treatment of patients with epilepsy and other neurological and psychiatric disorders.
Johannessen Landmark
Cecilie
C
Department of Pharmacy, Faculty of Health Sciences, Oslo University College, Oslo, Norway. cecilie.landmark@hf.hio.no
Johannessen
Svein I
SI
D000818:Animals; D000927:Anticonvulsants / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004827:Epilepsy / Q000188:drug therapy*; D006801:Humans
D000927:Anticonvulsants
Mol Pharmacol. 2000 Sep;58(3):591-600
10953053
Drug Metab Dispos. 2007 Apr;35(4):554-65
16936066
Perspect Medicin Chem. 2008 Feb 14;2:21-39
19787095
Mol Pharmacol. 2008 Jan;73(1):157-69
17940193
Epilepsia. 2008 Oct;49(10):1787-94
18494790
Proc Natl Acad Sci U S A. 2004 Jun 29;101(26):9861-6
15210974
Lancet. 2000 Nov 11;356(9242):1638-42
11089822
J Clin Pharmacol. 2002 Feb;42(2):175-82
11831540
Acta Neurol Scand Suppl. 2005;181:68-72
16238713
Proc Natl Acad Sci U S A. 2008 Feb 26;105(8):3128-33
18272489
Epilepsia. 2007 Mar;48(3):497-504
17319919
Epilepsy Res. 2008 Mar;79(1):22-30
18280116
Neurology. 2007 Nov 27;69(22):2045-53
17872363
Drug Metab Dispos. 1999 May;27(5):613-22
10220491
Expert Opin Investig Drugs. 2008 Mar;17(3):361-9
18321235
Epilepsy Res. 2006 Jun;69(3):273-94
16621450
Epilepsia. 2008 Jul;49(7):1213-20
18325020
Epilepsia. 2008 Jul;49(7):1123-41
18503564
Neurotherapeutics. 2007 Jan;4(1):149-54
17199031
Epilepsia. 2008 Feb;49(2):343-8
18028411
Epilepsia. 2007 Jul;48(7):1328-38
17381436
Epilepsia. 2006 Nov;47(11):1830-40
17116022
Drug Metab Dispos. 2008 Jan;36(1):36-45
17908923
Med Sci Monit. 2007 Jan;13(1):RA1-7
17179916
Neuropharmacology. 2002 Mar;42(3):346-52
11897113
Neurology. 2008 May 20;70(21):1950-8
18401024
Epilepsia. 2004 Dec;45(12):1498-505
15571507
Nat Med. 2004 Jul;10(7):685-92
15229516
Neurotherapeutics. 2007 Jan;4(1):84-7
17199019
Br J Clin Pharmacol. 2008 Jul;66(1):71-5
18341673
J Med Chem. 1999 Jul 15;42(14):2582-7
10411478
Nat Rev Neurosci. 2004 Jul;5(7):553-64
15208697
Br J Clin Pharmacol. 2003 Jul;56(1):39-45
12848774
Br J Pharmacol. 2002 Jul;136(5):659-72
12086975
Neurochem Int. 2002 Apr;40(5):435-40
11821151
Epilepsia. 2008 Mar;49(3):393-9
17822432
Epilepsia. 1999 Nov;40(11):1618-26
10565591
Neurosci Lett. 2000 Mar 17;282(1-2):73-6
10713399
Neurotherapeutics. 2007 Jan;4(1):106-9
17199023
Neurotherapeutics. 2007 Jan;4(1):123-5
17199026
CNS Drugs. 2008;22(1):27-47
18072813
Epilepsy Res. 2007 Oct;77(1):36-43
17890056
Eur J Pharmacol. 1996 May 15;303(3):163-9
8813562
Epilepsy Res. 2004 Sep-Oct;61(1-3):1-48
15570674
Neurotherapeutics. 2007 Jan;4(1):88-96
17199020
Epilepsia. 2008 Mar;49(3):418-24
17888078
Neurotherapeutics. 2007 Jan;4(1):145-8
17199030
Epilepsia. 2008 Jul;49(7):1239-76
18397299
Epilepsy Res. 2008 May;79(2-3):158-65
18353614
J Med Chem. 2004 Jan 29;47(3):530-49
14736235
J Physiol. 2008 Apr 1;586(7):1791-801
18238816
Epilepsia. 2006 Nov;47(11):1822-9
17116021
Eur J Clin Pharmacol. 2008 Mar;64(3):267-73
18157705
Epilepsy Res. 2007 Jan;73(1):1-52
17158031
Epilepsy Behav. 2008 Jan;12(1):49-53
18086455
Epilepsy Res. 2003 Feb;53(1-2):95-106
12576171
Expert Rev Neurother. 2008 Jun;8(6):929-39
18505358
Br J Pharmacol. 2008 Aug;154(8):1662-71
18500360
Neurotherapeutics. 2007 Jan;4(1):155-62
17199032
Eur J Clin Pharmacol. 2003 Apr;58(12):795-802
12698305
J Child Neurol. 2006 Jun;21(6):496-502
16948934
Expert Opin Investig Drugs. 2006 Jun;15(6):637-47
16732716
Int J Clin Pharmacol Ther. 2008 Mar;46(3):119-30
18397682
Epilepsy Res. 1996 Apr;23(3):211-23
8739124
Epilepsia. 2006 Apr;47(4):704-16
16650136